1.
|
Awakura Y, Ito N, Nakamura E, Takahashi T,
Kotani H, Mikami Y, Manabe T, Kamoto T, Habuchi T and Ogawa O:
Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma
in a Japanese population. Cancer Lett. 241:59–63. 2006. View Article : Google Scholar : PubMed/NCBI
|
2.
|
Nagase H and Woessner JF: Matrix
metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
|
3.
|
Declerck YA, Mercurio AM, Stack MS,
Chapman HA, Zutter MM and Muschel RJ: Proteases, extracellular
matrix and cancer: a workshop of the path B study section. Am J
Pathol. 164:1131–1139. 2004. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Di Nezza LA, Misajon A and Zhang J:
Presence of active gelatinases in endometrial carcinoma and
correlation of matrix metalloproteinase expression with increasing
tumor grade and invasion. Cancer. 94:1466–1475. 2002.
|
5.
|
Egelblad M and Werb Z: New functions for
the matrix metal-loproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
6.
|
Jiang WG, Davies G, Martin TA, Parr C,
Watkins G, Mason MD and Mansel RE: Expression of membrane type-1
matrix metal-loproteinase, MT1-MMP in human breast cancer and its
impact on invasiveness of breast cancer cells. Int J Mol Med.
17:583–590. 2006.PubMed/NCBI
|
7.
|
Ogata Y, Miura K, Ohkita A, Nagase H and
Shirouzu K: Imbalance between matrix metalloproteinase 9 and tissue
inhibitor of metalloproteinases 1 expression by tumor cells
implicated in liver metastasis from colorectal carcinoma. Kurume
Med J. 48:211–218. 2001. View Article : Google Scholar
|
8.
|
Moore CS and Crocker SJ: An alternate
perspective on the roles of TIMPs and MMPs in pathology. Am J
Pathol. 180:12–16. 2012. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Hahne JC, Fuchs T, El Mustapha H, Okuducu
AF, Bories JC and Wernert N: Expression pattern of matrix
metalloproteinase and TIMP genes in fibroblasts derived from Ets-1
knock-out mice compared to wild-type mouse fibroblasts. Int J Mol
Med. 18:153–159. 2006.PubMed/NCBI
|
10.
|
Abdel-Wahed MM, Asaad NY and Aleskandarany
M: Expression of matrix metalloproteinase-2 in renal cell
carcinoma. J Egypt Natl Canc Inst. 16:168–177. 2004.PubMed/NCBI
|
11.
|
Aoyama T, Yamamoto S, Kanematsu A, Ogawa O
and Tabata Y: Local delivery of matrix metalloproteinase gene
prevents the onset of renal sclerosis in streptozocin-induced
diabetic mice. Tissue Eng. 9:1289–1296. 2003. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Hirata H, Naito K, Yoshihiro S, Matsuyama
H, Suehiro Y and Hinoda Y: A single nucleotide polymorphism in the
matrix metalloproteinase-1 promoter is associated with conventional
renal cell carcinoma. Int J Cancer. 106:372–374. 2003. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Hirata H, Okayama N, Naito K, Inoue R,
Yoshihiro S, Matsuyama H, Suehiro Y, Hamanaka Y and Hinoda Y:
Association of a haplotype of matrix metalloproteinase (MMP)-1 and
MMP-3 polymorphisms with renal cell carcinoma. Carcinogenesis.
25:2379–2384. 2004. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Huo N, Ichikawa Y and Kamiyama M: MMP-7
(matrilysin) accelerated growth of human umbilical vein endothelial
cells. Cancer Lett. 177:95–100. 2002. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Miyata Y, Iwata T, Maruta S, Kanda S,
Nishikido M, Koga S and Kanetake H: Expression of matrix
metalloproteinase-10 in renal cell carcinoma and its prognostic
role. Eur Urol. 52:791–597. 2007. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Struckmann K, Mertz KD, Steu S, Storz M,
Staller P, Krek W, Schraml P and Moch H: pVHL co-ordinately
regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell
renal cell carcinoma. J Pathol. 214:464–471. 2008. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Yang SD, Sun RC, Mu HJ, Xu ZQ and Zhou ZY:
The expression and clinical significance of TGF-β1 and MMP2 in
human renal clear cell carcinoma. Int J Surg Pathol. 18:85–93.
2010.
|
18.
|
Eble JN, Sauter G, Epstein JI and
Sesterhenn IA: World Health Organization Classification of Tumors.
Pathology and Genetics of Tumors of the Urinary System and Male
Genital Organs. IARC Press; Lyon, France: pp. 16–18. 2004
|
19.
|
Lu H, Gan M, Zhang G, Zhou T, Yan M and
Wang S: Expression of survivin, caspase-3 and p53 in cervical
cancer assessed by tissue microarray: correlation with
clinicopathology and prognosis. Eur J Gynaecol Oncol. 6:662–666.
2010.PubMed/NCBI
|
20.
|
Johansson N, Ahonen M and Kahari VM:
Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci.
57:5–15. 2000. View Article : Google Scholar
|
21.
|
Stetler-Stevenson WG, Liotta LA and
Kleiner DE: Extracellular matrix 6: role of matrix
metalloproteinases in tumor invasion and metastasis. Faseb J.
7:1434–1441. 1993.PubMed/NCBI
|
22.
|
Stetler-Stevenson WG and Yu AE: Proteases
in invasion: matrix metalloproteinases. Semin Cancer Biol.
11:143–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
23.
|
Kawata N, Nagane Y, Hirakata H, Ichinose
T, Okada Y, Yamaguchi K and Takahashi S: Significant relationship
of matrix metalloproteinase 9 with nuclear grade and prognostic
impact of tissue inhibitor of metalloproteinase 2 for incidental
clear cell renal cell carcinoma. Urology. 69:1050–1053. 2007.
View Article : Google Scholar
|
24.
|
Kawata N, Nagane Y and Igarashi T: Strong
significant correlation between MMP-9 and systemic symptoms in
patients with localized renal cell carcinoma. Urology. 68:523–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
25.
|
Miyata Y, Iwata T, Ohba K, Kanda S,
Nishikido M and Kanetake H: Expression of matrix
metalloproteinase-7 on cancer cells and tissue endothelial cells in
renal cell carcinoma: prognostic implications and clinical
significance for invasion and metastasis. Clin Cancer Res.
12:6998–7003. 2006. View Article : Google Scholar
|
26.
|
Kumaki F, Matsui K and Kawai T: Expression
of matrix metal-loproteinases in invasive pulmonary adenocarcinoma
with bronchioloalveolar component and atypical adenomatous
hyperplasia. Am J Pathol. 159:2125–2135. 2001. View Article : Google Scholar
|